Paper Review Records
全部论文审稿周期
19 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
169
天
Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR -altered non-small-cell lung cancer
作者
Natasha B. Leighl; Antonio Passaro; Hiroaki Akamatsu; Alexander I. Spira; Danny Nguyen; Angel Qin; Julia Schuchard; Mohamed Gamil; Mahadi Baig; Mariam Alexander展开收起
作者单位
1. aPrincess Margaret Cancer Centre, Toronto, ON, Canada; 2. bDivision of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy; 3. cInternal Medicine III, Wakayama Medical University, Wakayama, Japan; 4. dVirginia Cancer Specialists, Fairfax, VA, USA; 5. eCity of Hope National Medical Center, Duarte, CA, USA; 6. fUniversity of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; 7. gJohnson & Johnson, Horsham, PA, USA; 8. hJohnson & Johnson, Spring House, PA, USA; 9. iJohnson & Johnson, Raritan, NJ, USA; 10. jHollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA展开收起
62
天
Cancer control after pausing treatment with larotrectinib in responding children with sarcoma and a TRK fusion: a plain language summary
作者
Leo Mascarenhas; Christopher Ollis; Yuvraj Singh; Linet Menachery; Domnita-Ileana Burcoveanu; Esther De La Cuesta; Cornelis M van Tilburg; Theodore W Laetsch展开收起
作者单位
1. aGuerin Children’s and Cedars-Sinai Cancer, Cedars-Sinai Health Sciences University, Los Angeles, CA, USA; 2. bPatient author; 3. cValley Springs, CA, USA; 4. dCaregiver author, Gurugram, Haryana, India; 5. eCaregiver author, White Plains, NY, USA; 6. fBayer HealthCare Pharmaceuticals, Inc, Basel, Switzerland; 7. gBayer HealthCare Pharmaceuticals, Inc, Whippany, NJ, USA; 8. hHopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; 9. iClinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany; 10. jHeidelberg University, Heidelberg Faculty of Medicine, Department of Pediatric Oncology, Hematology, Immunology, and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany; 11. kNational Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany; 12. lChildren’s Hospital of Philadelphia / University of Pennsylvania, Philadelphia, PA, USA展开收起
163
天
Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors
作者
Menghua Xia; Weifu Lv; Wei Zhao; Liqin Bi; Xueran Guo; Mengxia Zhang; Liangping Shi展开收起
作者单位
1. The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China展开收起
183
天
Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences
作者
Matthew Quaife; Cecilia Jimenez-Moreno; Blanca Gros Otero; Aisha Asra; Niodita Gupta-Werner; Katharine S. Gries; Marie-Kristin Leisten; Kathryn Matt; Robin Carson; Robyn Dennis; Jianming He; Bennett Levitan; Sacheeta Bathija展开收起
作者单位
1. Evidera; 2. Johnson & Johnson展开收起
196
天
Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study
作者
Shan Xu; Hao Yang; Nan Hu展开收起
作者单位
1. The Third Affiliated Hospital of Nanjing Medical University; 2. The Third Affiliated Hospital of Soochow University展开收起
239
天
A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing
作者
İmdat Eroğlu; Sıla Soylu Koçoğlu; Eron Merovci; Gözde Savaş; Fatih Gürler; Osman Sutcuoglu; Ugur Coskun; Aytug Uner; Murat Ucar; Burak Karaarslan; Ahmet Özet; Nuriye Özdemir; Ozan Yazıcı展开收起
作者单位
1. Gazi University School of Medicine展开收起
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
